Title |
Tricyclic drugs for depression in children and adolescents
|
---|---|
Published in |
Cochrane database of systematic reviews, June 2013
|
DOI | 10.1002/14651858.cd002317.pub2 |
Pubmed ID | |
Authors |
Philip Hazell, Mohsen Mirzaie |
Abstract |
There is a need to identify effective and safe treatments for depression in children and adolescents. While tricyclic drugs are effective in treating depression in adults, individual studies involving children and adolescents have been equivocal. Prescribing of tricyclic drugs for depression in children and adolescents is now uncommon, but an accurate estimate of their efficacy is helpful as a comparator for other drug treatments for depression in this age group. This is an update of a Cochrane review first published in 2000 and updated in 2002, 2006 and 2010. |
X Demographics
The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 5 | 22% |
Mexico | 4 | 17% |
Namibia | 1 | 4% |
United States | 1 | 4% |
France | 1 | 4% |
Unknown | 11 | 48% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 21 | 91% |
Practitioners (doctors, other healthcare professionals) | 1 | 4% |
Scientists | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 343 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
South Africa | 1 | <1% |
United Kingdom | 1 | <1% |
Spain | 1 | <1% |
Japan | 1 | <1% |
United States | 1 | <1% |
Unknown | 338 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 46 | 13% |
Student > Bachelor | 44 | 13% |
Student > Ph. D. Student | 33 | 10% |
Researcher | 29 | 8% |
Student > Doctoral Student | 24 | 7% |
Other | 56 | 16% |
Unknown | 111 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 95 | 28% |
Psychology | 52 | 15% |
Social Sciences | 15 | 4% |
Nursing and Health Professions | 14 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 8 | 2% |
Other | 29 | 8% |
Unknown | 130 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2021.
All research outputs
#2,441,747
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#4,938
of 11,499 outputs
Outputs of similar age
#20,335
of 209,578 outputs
Outputs of similar age from Cochrane database of systematic reviews
#105
of 264 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,578 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 264 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.